The addition of atezolizumab to TDM-1 did not show any improvement and was associated with more adverse events in previously treated HER2-positive locally advanced or metastatic BC patients who received prior trastuzumab and taxane based therapies. This evidence concerns the gene ERBB2 and breast cancer.